Essential (primary) hypertension — outpatient management
Chronic BP control · Cardiac
Physician-written · Verified by three sets of doctors · Reviewed November 2026
Bedside summary
Essential hypertension is managed by confirming diagnosis with out-of-office readings, assessing total cardiovascular risk and target-organ damage, then combining lifestyle change with staged pharmacotherapy to a BP target of generally <140/90 (or <130/80 in many).
Red flags
- BP ≥180/120 with target-organ symptoms (emergency)
- New visual disturbance or neurological symptoms
- Signs of acute kidney injury after RAAS blockade
- Features of phaeochromocytoma or Cushing's
- Resistant hypertension in a young patient
Assessment
Differential diagnosis
- Secondary hypertension (renal, endocrine)
- White-coat hypertension
- Masked hypertension
- Medication/substance-induced rise (NSAIDs, decongestants)
- Obstructive sleep apnoea-related
- Isolated systolic hypertension of ageing
Investigations
- Ambulatory or home BP monitoring to confirm diagnosis
- U&E, eGFR and urine ACR for renal involvement
- Fasting glucose/HbA1c and lipid profile
- 12-lead ECG for LVH and ischaemia
- Fundoscopy for hypertensive retinopathy
- Calculate 10-year cardiovascular risk
Management
- Confirm sustained hypertension with ABPM or home readings, not single clinic values
- Screen for secondary causes if young, resistant, or abrupt/severe
- Assess target-organ damage and global cardiovascular risk
- Advise lifestyle measures: salt reduction, weight loss, exercise, alcohol limits, DASH-type diet
- Start drug therapy based on age/ethnicity: ACEi/ARB for <55 and non-Black, CCB for ≥55 or Black
- Combine an ACEi/ARB with a CCB or thiazide-like diuretic as step 2
- Use all three classes together as step 3 before labelling resistant
- Target <140/90 for most; aim <130/80 if tolerated, diabetes, CKD or high risk
- Avoid ACEi plus ARB combination due to renal and hyperkalaemia risk
- Recheck U&E 1-2 weeks after starting/uptitrating ACEi/ARB or diuretic
- Review adherence and home readings at each visit
- Escalate to spironolactone-based therapy if BP uncontrolled on three agents
Drugs & doses
Amlodipine 5-10 mg PO OD
Ramipril 2.5-10 mg PO OD (or lisinopril, perindopril)
Losartan 50-100 mg PO OD (or candesartan 8-32 mg OD) if ACEi not tolerated
Indapamide 1.5-2.5 mg PO OD (thiazide-like diuretic)
Spironolactone 25-50 mg PO OD for step 4 if potassium ≤4.5 mmol/L
Doxazosin MR 4-8 mg PO OD or bisoprolol 5-10 mg OD as alternative step 4
Disposition
GP-led chronic management with lifestyle support. Refer to specialist for resistant, secondary, or very young-onset hypertension.
Complications & pitfalls
- Stroke and cognitive decline
- Ischaemic heart disease and heart failure
- Chronic kidney disease progression
- Hypertensive retinopathy
- Aortic aneurysm/dissection
Exam pearls
- Thiazide-like diuretics (indapamide) are preferred over thiazides (bendroflumethiazide) for outcomes
- A rise in creatinine up to 30% after starting an ACEi/ARB is acceptable
- Home BP targets run ~5 mmHg lower than clinic targets
- Single-pill combinations improve adherence and control
- Check for non-adherence and white-coat effect before escalating in apparent resistance
Disclaimer: Educational decision support for qualified clinicians and students — not a substitute for clinical judgement, local protocols or a full drug reference. Confirm every dose and contraindication against your formulary before prescribing.